Tukysa is a cancer medicine that is used to treat breast cancer that is locally advanced or metastatic (has spread to other parts of the body) and when it is HER2\-positive. This means the cancer cells produce a protein on their surface, HER2, which stimulates the growth of the cancer. Tukysa is used with two other medicines, capecitabine and trastuzumab, and is used after at least 2 other treatments for HER2\-positive cancer have already been tried. The active substance in Tukysa is tucatinib.
Therapeutic Indication
Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2?positive locally advanced or metastatic breast cancer who have received at least 2 prior anti\-HER2 treatment regimens.
Therapeutic Area (MeSH)
ATC Code
L01EH03
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Tukysa
Medicine Name
Tukysa
Aliases
N/ANo risk management plan link.
